Provided by Tiger Trade Technology Pte. Ltd.

Repligen

181.70
+4.472.52%
Post-market: 181.700.00000.00%16:10 EDT
Volume:1.37M
Turnover:249.48M
Market Cap:10.23B
PE:248.90
High:186.52
Open:179.32
Low:178.00
Close:177.23
52wk High:198.87
52wk Low:100.99
Shares:56.29M
Float Shares:53.32M
Volume Ratio:0.99
T/O Rate:2.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7300
EPS(LYR):0.8600
ROE:1.99%
ROA:1.40%
PB:4.84
PE(LYR):211.28

Loading ...

Repligen (RGEN) Stock Looks Stretched After A 32% One Year Run

Simply Wall St.
·
Yesterday

Q/C Technologies Teams with Sandia National Labs on Nanophotonics Research for Optical AI Inference Chip

Reuters
·
Sep 30

Repligen Buy Rating Reiterated as Analyst Sees Medium-Term Growth Catalysts; Price Target Maintained at $225

TIPRANKS
·
Sep 29

Repligen CEO Olivier Loeillot Disposes of Common Shares Worth $2,460,700

Reuters
·
Sep 26

Q/C Technologies CTO Yossef Ehrlichman Files Initial Beneficial Ownership Statement

Reuters
·
Sep 23

Repligen CEO Olivier Loeillot Disposes of Common Shares Worth $976,680

Reuters
·
Sep 23

Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer

Reuters
·
Sep 19

Repligen (RGEN) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Sep 16

Repligen announces long-serving director Karen Dawes’ retirement

TIPRANKS
·
Sep 16

Q/C Technologies Director Chelsea Voss Resigns from Board

Reuters
·
Sep 12

BioLife Solutions Nears Completion of Repligen Acquisition

TIPRANKS
·
Sep 10

BioLife Solutions Announces Special Shareholder Meeting on Merger Agreement

Reuters
·
Sep 10

Repligen Outlines Strategy to Drive Mid-Teens Revenue CAGR Through 2030, Targets ~30% Adjusted Ebitda Margin

Reuters
·
Sep 10

UBS Adjusts Price Target on Repligen to $225 From $195, Keeps Buy Rating

MT Newswires Live
·
Sep 09

Repligen clears antitrust hurdle in BioLife Solutions acquisition

TIPRANKS
·
Sep 09

Repligen Says HSR Waiting Period Expires for BioLife Solutions Deal

Reuters
·
Sep 09

Repligen CEO Olivier Loeillot Disposes of USD 985,896.05 in Common Shares

Reuters
·
Sep 09

BioLife Solutions Sets October Vote on Cash‑and‑Stock Merger With Repligen

TIPRANKS
·
Sep 05

Repligen (RGEN) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.
·
Aug 29

Will Stronger 2026 Guidance and Broad-Based Growth Change Repligen's (RGEN) Narrative

Simply Wall St.
·
Aug 28